Literature DB >> 11598071

Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.

R Hertle1, R Mrsny, D J Fitzgerald.   

Abstract

Pseudomonas aeruginosa is the major infectious agent of concern for cystic fibrosis patients. Strategies to prevent colonization by this bacterium and/or neutralize its virulence factors are clearly needed. Here we characterize a dual-function vaccine designed to generate antibodies to reduce bacterial adherence and to neutralize the cytotoxic activity of exotoxin A. To construct the vaccine, key sequences from type IV pilin were inserted into a vector encoding a nontoxic (active-site deletion) version of exotoxin A. The chimeric protein, termed PE64Delta553pil, was expressed in Escherichia coli, refolded to a near-native conformation, and then characterized by various biochemical and immunological assays. PE64Delta553pil bound specifically to asialo-GM1, and, when injected into rabbits, produced antibodies that reduced bacterial adherence and neutralized the cell-killing activity of exotoxin A. Results support further evaluation of this chimeric protein as a vaccine to prevent Pseudomonas colonization in susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598071      PMCID: PMC100076          DOI: 10.1128/IAI.69.11.6962-6969.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  54 in total

1.  Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.

Authors:  S J Cryz; J C Sadoff; E Fürer; R Germanier
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

2.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.

Authors:  J M Matthews-Greer; H E Gilleland
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

4.  Long-term tobramycin aerosol therapy in cystic fibrosis.

Authors:  G Steinkamp; B Tümmler; M Gappa; A Albus; J Potel; G Döring; H von der Hardt
Journal:  Pediatr Pulmonol       Date:  1989

5.  Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue.

Authors:  M Lukac; G B Pier; R J Collier
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.609

6.  Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.

Authors:  S J Cryz; A B Lang; J C Sadoff; R Germanier; E Fürer
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.609

7.  A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Fürer; J C Sadoff; R Germanier
Journal:  Antibiot Chemother (1971)       Date:  1987

8.  Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

Authors:  J Hwang; D J Fitzgerald; S Adhya; I Pastan
Journal:  Cell       Date:  1987-01-16       Impact factor: 66.850

9.  Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors:  T Matsumoto; K Tateda; N Furuya; S Miyazaki; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  J Med Microbiol       Date:  1998-04       Impact factor: 3.196

Review 10.  The role of exotoxin A in pseudomonas disease and immunity.

Authors:  M Pollack
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec
View more
  10 in total

1.  Genetic characterization indicates that a specific subpopulation of Pseudomonas aeruginosa is associated with keratitis infections.

Authors:  Rosalind M K Stewart; Lutz Wiehlmann; Kevin E Ashelford; Stephanie J Preston; Eliane Frimmersdorf; Barry J Campbell; Timothy J Neal; Neil Hall; Stephen Tuft; Stephen B Kaye; Craig Winstanley
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

Review 3.  Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.

Authors:  Jeffrey L Veesenmeyer; Alan R Hauser; Thiago Lisboa; Jordi Rello
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

4.  Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells.

Authors:  Jennifer C Hsieh; Doris M Tham; Weijun Feng; Fan Huang; Selamawit Embaie; Keyi Liu; Deborah Dean; Ralf Hertle; David J Fitzgerald; Randall J Mrsny
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.609

5.  Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae.

Authors:  Sam Maher; Linda Feighery; David J Brayden; Siobhán McClean
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.580

6.  Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.

Authors:  Asghar Tanomand; Safar Farajnia; Shahin Najar Peerayeh; Jafar Majidi
Journal:  Iran Biomed J       Date:  2013

7.  Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model.

Authors:  Leila Safari Zanjani; Reza Shapouri; Mehrouz Dezfulian; Mehdi Mahdavi; Mehdi Shafiee Ardestani
Journal:  World J Microbiol Biotechnol       Date:  2019-06-11       Impact factor: 4.253

Review 8.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

9.  Preparation and evaluation of the exotoxin A nano-gold conjugate as a vaccine candidate for Pseudomonas aeruginosa infections.

Authors:  Masoumeh Abbasi; Asghar Tanomand; Farshid Kafilzadeh; Samaneh Zolghadri; Hasan Hosainzadegan
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

Review 10.  Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections.

Authors:  Luke L Proctor; Whitney L Ward; Conner S Roggy; Alexandra G Koontz; Katie M Clark; Alyssa P Quinn; Meredith Schroeder; Amanda E Brooks; James M Small; Francina D Towne; Benjamin D Brooks
Journal:  Antibiotics (Basel)       Date:  2021-12-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.